143 related articles for article (PubMed ID: 15582249)
1. 1,25 Dihydroxyvitamin D(3) receptor expression in superficial transitional cell carcinoma of the bladder: a possible prognostic factor?
Sahin MO; Canda AE; Yorukoglu K; Mungan MU; Sade M; Kirkali Z
Eur Urol; 2005 Jan; 47(1):52-7. PubMed ID: 15582249
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
3. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
4. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
Tokunaga H; Lee DH; Kim IY; Wheeler TM; Lerner SP
Clin Cancer Res; 1999 Sep; 5(9):2520-5. PubMed ID: 10499628
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
Suzuki K; Morita T; Tokue A
Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
9. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
10. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder.
Mungan MU; Canda AE; Tuzel E; Yorukoglu K; Kirkali Z
Eur Urol; 2005 Nov; 48(5):760-3. PubMed ID: 16005563
[TBL] [Abstract][Full Text] [Related]
12. Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer.
Oka N; Yamamoto Y; Takahashi M; Nishitani M; Kanayama HO; Kagawa S
BJU Int; 2005 Mar; 95(4):660-3. PubMed ID: 15705099
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder.
Basakci A; Kirkali Z; Tuzel E; Yorukoglu K; Mungan MU; Sade M
Eur Urol; 2002 Mar; 41(3):342-5. PubMed ID: 12180239
[TBL] [Abstract][Full Text] [Related]
14. Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder.
Yamasaki Y; Smith C; Weisz D; van Huizen I; Xuan J; Moussa M; Stitt L; Hideki S; Cherian MG; Izawa JI
Urology; 2006 Mar; 67(3):530-5. PubMed ID: 16504266
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer.
Becker M; Szarvas T; Wittschier M; vom Dorp F; Tötsch M; Schmid KW; Rübben H; Ergün S
Cancer; 2010 Oct; 116(19):4502-12. PubMed ID: 20564745
[TBL] [Abstract][Full Text] [Related]
16. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of proliferating cell nuclear antigen expression in transitional cell carcinoma of the upper urinary tract.
Cheng HL; Chow NH; Tzai TS; Tong YC; Lin JS; Chan SH; Yang WH; Chang CC; Lin YM
Anticancer Res; 1997; 17(4A):2789-93. PubMed ID: 9252716
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
[TBL] [Abstract][Full Text] [Related]
19. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.
Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L
Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis.
Zu X; Tang Z; Li Y; Gao N; Ding J; Qi L
BJU Int; 2006 Nov; 98(5):1090-3. PubMed ID: 17034609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
